Monday, 7 July 2014

Sun-Ranbaxy deal pushes domestic H1, M&As jump 22%.

The average M&A deal size climbed to USD 95 million during the reporting period from USD 62.8 million the same period last year.

he mergers and acquisition (M&A) activity involving domestic companies jumped 21.9 percent at USD 20.5 billion in the first half of 2014 over the same period last year, says a report. "The value of announced M&A deals involving companies reached USD 20.5 billion during the first half of 2014 despite a 11.2 percent slowdown in the number of deals from 582 to 517," a report by Thomson Reuters said today. The average M&A deal size climbed to USD 95 million during the reporting period from USD 62.8 million the same period last year. Domestic M&As stood at USD 10.1 billion, up 295.9 percent compared to the first half of 2013. "This was driven by Sun Pharmaceutical 's pending acquisition of  Ranbaxy Labs  for USD 4 billion in a stock swap transaction. The deal pushed the healthcare sector to capture 39.6 percent of the domestic deal making," the report said. Completed M&A deals involving domestic companies totaled USD 14.9 billion, a 20.7 percent rise compared to the first half of 2013, the highest first half period since 2011 which was at USD 20.7 billion.

No comments:

Post a Comment